Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials
详细信息 查看全文
- 作者：Massimo Gentile ; Valeria Magarotto ; Massimo Offidani ; Pellegrino Musto ; Sara Bringhen ; Maria Teresa Petrucci ; Francesca Gay ; Alessandra Larocca ; Giuseppina Uccello ; Annamaria Petrungaro ; Ernesto Vigna ; Rosa Greco ; Anna Grazia Recchia ; Giovanni Tripepi ; Roberto Ria ; Francesco Di Raimondo ; Antonio Palumbo and Fortunato Morabito
- 刊名：American Journal of Hematology
- 出版年：2017
- 出版时间：March 2017
- 年：2017
- 卷：92
- 期：3
- 页码：244-250
- 全文大小：583K
- ISSN：1096-8652
文摘
There are currently no direct head-to-head clinical trials evaluating bortezomib-melphalan-prednisone (VMP) versus lenalidomide and low-dose dexamethasone (Rd). VMP (257 cases) and Rd (222 cases) arms of two randomized phase III trials were employed to assess the treatment influence on outcome in untreated elderly MM patients.